Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) Invested Capital: 2010-2025

Historic Invested Capital for Vanda Pharmaceuticals (VNDA) over the last 15 years, with Sep 2025 value amounting to $466.0 million.

  • Vanda Pharmaceuticals' Invested Capital fell 13.90% to $466.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $466.0 million, marking a year-over-year decrease of 13.90%. This contributed to the annual value of $543.5 million for FY2024, which is 0.26% down from last year.
  • Latest data reveals that Vanda Pharmaceuticals reported Invested Capital of $466.0 million as of Q3 2025, which was down 4.18% from $486.3 million recorded in Q2 2025.
  • Vanda Pharmaceuticals' Invested Capital's 5-year high stood at $544.9 million during Q4 2023, with a 5-year trough of $466.0 million in Q3 2025.
  • For the 3-year period, Vanda Pharmaceuticals' Invested Capital averaged around $527.1 million, with its median value being $541.2 million (2024).
  • Per our database at Business Quant, Vanda Pharmaceuticals' Invested Capital rose by 12.31% in 2021 and then declined by 13.90% in 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' Invested Capital (Quarterly) stood at $504.9 million in 2021, then rose by 4.41% to $527.2 million in 2022, then rose by 3.36% to $544.9 million in 2023, then dropped by 0.26% to $543.5 million in 2024, then dropped by 13.90% to $466.0 million in 2025.
  • Its last three reported values are $466.0 million in Q3 2025, $486.3 million for Q2 2025, and $511.4 million during Q1 2025.